Skip to main content

RadNet, Inc. (RDNT) Stock Analysis

Recovery setup

SellModerate Confidence

Healthcare · Diagnostics & Research

Sell if holding. Engine safety override at $55.93: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 3.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Below long-term trend.

RadNet is the largest U.S. diagnostic imaging provider by locations and annual revenue, operating 418 multi-modality imaging centers in 9 states as of December 31, 2025. Revenue comes from MRI, CT, PET, mammography, and other imaging services reimbursed by Medicare, Medicaid,... Read more

$55.93+40.7% A.UpsideScore 4.9/10#20 of 25 Diagnostics & Research
Stop $51.98Target $78.63(analyst − 13%)A.R:R 3.9:1
Analyst target$90.38+61.6%8 analysts
$78.63our TP
$55.93price
$90.38mean
$100

Sell if holding. Engine safety override at $55.93: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 3.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 52. Score 4.9/10, moderate confidence.

Passes 6/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Suitability: aggressive.

Thesis

Rewards
No bull case signals
Risks
Quality below floor (2.8 < 4.0)

Key Metrics

P/E (TTM)
P/E (Fwd)52.7
Mkt Cap$4.4B
EV/EBITDA23.4
Profit Mgn-0.9%
ROE1.4%
Rev Growth14.8%
Beta1.53
DividendNone
Rating analysts14

Quality Signals

Piotroski F6/9

Options Flow

P/C0.94neutral
IV81%elevated
Max Pain$40-28.5% vs spot

Concentration Risks(10-K Item 1A)

  • MEDIUMCustomerMedicare or Medicaid
    10-K Item 1A: 'A significant portion of our business is derived from federal and state reimbursement programs such as Medicare or Medicaid.'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History
0.0
Surprise Avg
0.0
Erm
5.0
Earnings Timing
5.0
Earnings concerns: 1B/3MEarnings in 10 days

Unprofitable operations — net margin -0.9%. Quality floor flags this regardless of sector context.static

Gross Margin
0.0
Net Margin
0.0
Roe
0.5
Roa
1.1
Operating Margin
2.7
Moat
5.0
Current Ratio
6.3
Piotroski F
6.7
No competitive moatQuality concerns

Volatile — 5.2% daily ATR makes tight stops impractical. Position-size conservatively.static

Days To Cover
0.0
Volatility
0.0
Implied Vol
0.0
Max Pain Risk
3.0
Short Interest
3.3
Debt Equity
4.3
Beta
4.9
Put Call
7.1
High IV: 81%Above max pain $40
GatesMomentum 5.2<5.5 (soft — BUY_NOW allowed but watch)EARNINGS PROXIMITY 10d<=14d (soft)Momentum 5.2>=4.5A.R:R 3.9 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARRecoverySuitability: Aggressive
RSI
52 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $52.39Resistance $63.50

Price Targets

$52
$79
A.Upside+40.6%
A.R:R3.9:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (2.8 < 4.0)

Earnings

B
M
M
M
1/4 beats
Next Earnings2026-05-10 (10d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is RDNT stock a buy right now?

Sell if holding. Engine safety override at $55.93: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 3.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 52. Prior stop was $51.98. Score 4.9/10, moderate confidence.

What is the RDNT stock price target?

Take-profit target: $78.63 (+40.7% upside). Prior stop was $51.98. Stop-loss: $51.98.

What are the risks of investing in RDNT?

Quality below floor (2.8 < 4.0).

Is RDNT overvalued or undervalued?

RadNet, Inc. trades at a P/E of N/A (forward 52.7). TrendMatrix value score: 6.0/10. Verdict: Sell.

What do analysts say about RDNT?

14 analysts cover RDNT with a consensus score of 4.3/5. Average price target: $90.

What does RadNet, Inc. do?RadNet is the largest U.S. diagnostic imaging provider by locations and annual revenue, operating 418 multi-modality...

RadNet is the largest U.S. diagnostic imaging provider by locations and annual revenue, operating 418 multi-modality imaging centers in 9 states as of December 31, 2025. Revenue comes from MRI, CT, PET, mammography, and other imaging services reimbursed by Medicare, Medicaid, and commercial insurers; its Digital Health segment sells AI-powered radiology software.

Related stocks: WGS (GeneDx Holdings Corp.) · NEO (NeoGenomics, Inc.) · SHC (Sotera Health Company) · BLLN (BillionToOne, Inc.) · QGEN (Qiagen N.V.)